Tenax Therapeutics(TENX) - 2025 Q4 - Annual Report

Clinical Trials and Development - The company is conducting two Phase 3 clinical trials for oral levosimendan, which are expected to be expensive and time-consuming[23] - The company is conducting two Phase 3 clinical trials, LEVEL and LEVEL-2, for oral levosimendan, which are both expensive and time-consuming[23] - The company requires substantial additional funding to further develop and commercialize its product candidates, including completing ongoing clinical trials[23] - The company expects to incur substantial additional funding needs to further develop and commercialize its product candidates, including completing ongoing clinical trials[23] - The company relies heavily on third parties for conducting nonclinical testing and clinical studies, which poses risks to product development timelines[26] - The company is dependent on third parties for conducting nonclinical testing and clinical studies, which poses risks to the development of its product candidates[26] Financial Performance and Profitability - The company has incurred losses since inception and expects to continue incurring losses in the foreseeable future, with no guarantee of ever becoming profitable[24] - The company has incurred losses since inception and expects to continue incurring losses in the foreseeable future[24] - The company expects its operating results to fluctuate on a quarterly and annual basis, making future performance difficult to predict[23] - The company may be required to make milestone and royalty payments related to the levosimendan intellectual property, affecting profitability if approved[23] Market and Competition - The market acceptance of the company's products remains uncertain, which could impact future revenue generation[23] - The market acceptance of the company's products remains uncertain, which could impact future revenue[23] - The company may face significant competition that could render its product candidates noncompetitive or obsolete[29] - The company may face significant competition that could render its product candidates noncompetitive or obsolete[29] Regulatory and Commercialization Challenges - The company is subject to extensive government regulation, which is difficult to predict and could delay or prevent product commercialization[29] - The company is subject to extensive government regulation, which is difficult to predict and could delay product approval[29] - The company has limited marketing capabilities and no sales organization, which may hinder successful commercialization of its products if approved[23] - The company has limited marketing capabilities and no sales organization, which could hinder successful commercialization of its products[26] - The company currently has no approved drug products for sale and cannot guarantee future marketable drug products[23] - The company may incur substantial liabilities from product liability lawsuits, which could limit commercialization efforts[29]